 |
|
|
|
Equipalazone 1 g Oral Powder is indicated in the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of Phenylbutazone can offer relief, for example, in lameness associated with osteoarthritic conditions, acute and chronic laminitis, bursitis and carpitis, and in the reduction of post-surgical soft tissue reaction.
|
|
Presentation
Free flowing white/cream powder for oral administration, containing 1 g micro-encapsulated Phenylbutazone per sachet.
Preservative: Sodium Paracombin 0.15%
Uses
For the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of phenylbutazone can offer relief. For example lameness associated with osteoarthritis conditions, acute and chronic laminitis, bursitis, carpitis.
|
|
Dosage and administration
Dependent on individual response, but as a guide:
For horses
450 kg (1,000 lb) body weight. The contents of two sachets to be administered twice on day one (equivalent to 8.8 mg/kg/day) followed by one sachet twice daily for four days (4.4 mg/kg/day), then one sachet daily or on alternate days sufficient to keep the horse comfortable (2.2 mg/kg/day).
For ponies
225 kg (500 lb) body weight. One sachet (4.4 mg/kg/day) on alternate days.
Adjust dose according to bodyweight.
Discontinue treatment if no response is evident after four to five days' treatment.
For ease of administration, Equipalazone may be mixed with a small quantity of bran or oats.
|
|
Contra-indications, warnings, etc
The product should be handled with care at all times to reduce the risk of accidental ingestion, skin contact or dust inhalation. If accidental skin or eye contact occurs, the site should be washed immediately with water. If the product is ingested, seek medical advice immediately and show the product packaging. Advice to doctors: gastric lavage (emesis in children) should be performed urgently. Charcoal haemoperfusion has also been shown to be beneficial. Treatment should then be administered symptomatically.
Do not use in horses intended for human consumption. The therapeutic index of Phenylbutazone is low. Do not exceed the stated dose or the duration of treatment. Use is contra indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
Use in any animal less than six weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a risk of increased renal failure.
Use during pregnancy should be avoided whenever possible, particularly during the first trimester.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.
General precautions
Keep out of the reach of children.
For animal treatment only.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections appropriate concurrent antimicrobial therapy should be instigated.
Pharmaceutical precautions
Store in a dry place. Store below 25°C.
|
|
Legal category
POM-V (previously POM).
Packaging Quantities
Boxes of 32 and 100 sachets.
Further information
The clinical effect of phenylbutazone can be evident of at least three days following cessation of administration. This should be borne in mind when examining horses for soundness.
Some racing authorities, (including the British Jockey Club) regard phenylbutazone as a “prohibited substance” within their rules of racing. The Royal College of Veterinary Surgeons has given guidance to the veterinary profession regarding the elimination time of various anti-inflammatory drugs and they state “if a veterinarian recommends the discontinuance of any such drug not less than eight days before racing (even though such a period may be longer than is necessary in many instances) he should be able to feel sure that he has catered for all but the most exceptional circumstances”.
Dispose of any unused product or containers in accordance with guidance from your local waste regulation authority, e.g. the local regional office of the Environment Agency or SEPA.
Marketing authorisation number
Vm 01732/4083.
|
|
|
